Lin Patrick 4

What Happened Lin Patrick, listed on the filing as the company's Chief Business & Strategy Officer, made an open-market purchase of 1,369 shares of Processa Pharmaceuticals (PCSA) on April 15, 2026. The shares were bought at $2.97 per share for a total reported cost of $4,066. This was a purchase (insider buying can be viewed more positively than selling), but the dollar amount is small.

Key Details

• Transaction date and price: 2026-04-15 — 1,369 shares at $2.97 each.
• Total value: $4,066.
• Shares owned after transaction: Not disclosed in the filing.
• Footnotes/plan: No 10b5-1 plan or other special footnotes reported in the Form 4.
• Filing timeliness: Form 4 was filed on 2026-04-17 for the 2026-04-15 transaction — appears to be filed within the required two business days (timely).

Context This was a modest open-market purchase (transaction code P). Small insider purchases can show personal conviction but, given the low dollar amount here, this single trade should be weighed alongside other insider activity and company fundamentals rather than taken as a strong signal on its own.